[1]杨 提,陆 燕,陈丽文,等.四种抗菌药物治疗老年患者社区获得性下尿路感染的成本-效果分析[J].医学信息,2022,35(02):157-159.[doi:10.3969/j.issn.1006-1959.2022.02.040]
　YANG Ti,LU Yan,CHEN Li-wen,et al.Cost-effect Analysis of Four Antimicrobial Drugs to Treat Urinary Tract Infectionsin the Elderly Community[J].Medical Information,2022,35(02):157-159.[doi:10.3969/j.issn.1006-1959.2022.02.040]
点击复制

四种抗菌药物治疗老年患者社区获得性下尿路感染的成本-效果分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年02期
页码:
157-159
栏目:
药物与临床
出版日期:
2022-01-15

文章信息/Info

Title:
Cost-effect Analysis of Four Antimicrobial Drugs to Treat Urinary Tract Infectionsin the Elderly Community
文章编号:
1006-1959（2022）02-0157-03
作者:
杨 提; 陆 燕; 陈丽文; 刘艳辉; 姚佳晨; 李文艳
上海市浦东新区公利医院药剂科，上海 200135
Author(s):
YANG Ti; LU Yan; CHEN Li-wen; LIU Yan-hui; YAO Jia-chen; LI Wen-yan
Department of Pharmacy,Shanghai Pudong New Area Gongli Hospital,Shanghai 200135,China
关键词:
抗菌药物; 成本-效果; 敏感度; 药物经济学
Keywords:
Antibacterial drugs; Cost-effect; Sensitivity; Pharmacoeconomics
分类号:
R378
DOI:
10.3969/j.issn.1006-1959.2022.02.040
文献标志码:
A
摘要:
目的 应用药物经济学原理对四种抗菌药物治疗老年尿路感染的成本-效果比进行分析，从中找出最佳的药物治疗方案。方法 选取2018年7月-2019年9月我院门诊确诊的老年尿路感染患者320例，根据抗菌药物治疗方案分为A组、B组、C组及D组，每组80例。A组口服头孢克肟分散片，B组口服磷霉素氨丁三醇散，C组口服盐酸左氧氟沙星分散片，D组口服左氧氟沙星片，比较各组临床疗效及不良反应，根据各组患者的药物治疗效果进行成本-效果及敏感度分析。结果 A组、B组、C组及D组的总有效率分别为76.25%、72.50%、61.25%和73.75%，四组间比较，差异无统计学意义（P＞0.05）；四组患者不良反应轻且均在可耐受范围内；A组、B组、C组及D组的成本-效果比分别为1.89、2.80、0.52和1.04，C组最低，D组次之；敏感度分析显示，C组＜D组＜A组＜B组。结论 从药物经济学角度分析，考虑药物治疗成本与疗效后，左氧氟沙星片的成本-效果比最低，为最佳给药方案。
Abstract:
Objective To analyze the cost-effect ratio of four antimicrobial drugs in the treatment of urinary tract infection in the elderly by using the principle of pharmacoeconomics, and to find out the best drug treatment scheme.Methods A total of 320 elderly patients with urinary tract infection diagnosed in our hospital from July 2018 to September 2019 were selected and divided into group A, group B, group C and group D according to the antibiotic treatment plan, with 80 cases in each group. Group A was treated with cefixime dispersible tablets, group B was treated with fosfomycin aminobutanol powder, group C was treated with levofloxacin hydrochloride dispersible tablets, and group D was treated with levofloxacin tablets. The clinical efficacy and adverse reactions of each group were compared. Cost-effect and sensitivity analysis were carried out according to the drug treatment effect of each group.Results The total effective rates of group A, group B, group C and group D were 76.25%, 72.50%, 61.25% and 73.75%, respectively; There was no significant difference between the four groups (P>0.05). The adverse reactions of the four groups were mild and tolerable; the cost-effect ratios of group A, group B, group C and group D were 1.89, 2.80, 0.52 and 1.04, respectively, which were the lowest in group C and the second in group D. Sensitivity analysis showed that group C

参考文献/References:

[1]Vivek V,Parveen K,Henrik T,et al.alpha-Hemolysin of uropathogenic E. coli regulates NLRP3 inflammasome activation and mitochondrial dysfunction in THP-1 macrophages[J].Sci Rep,2020,10(1): 12653.[2]Savita J,Arif H,Christa E,et al.Virulence characteristics and genetic affinities of multiple drug resistant uropathogenic Escherichia coli from a semi urban locality in India[J].PLoS One,2011,6(3):18063.[3]Haroon A,Daniel F,Shantini P,et al.Antibiotic prophylaxis and clinical outcomes among older adults with recurrent urinary tract infection: cohort study[J].Age Ageing,2019,48(2):228-234.[4]Flores-Mireles AL,Walker JN,Caparon M,et al.Urinary tract infections: epidemiology, mechanisms of infection and treatment options[J].Nat Rev Microbiol,2015,13(5):269-284.[5]Hyun SC,Seung JL,Tetsuro M.Summary of the UAA-AAUS guidelines for urinary tract infections[J].Int J Urol,2018,25(3):175-185.[6]尿路感染诊断与治疗中国专家共识编写组.尿路感染诊断与治疗中国专家共识(2015版)——复杂性尿路感染[J].中华泌尿外科杂志,2015,36(4):241-244.[7]Paul TO,Adedolapo OO,Opeyemi EO,et al.The Economic Impacts of Chronic Illness on Households of Patients in Ile-Ife, South-Western Nigeria[J].Cureus,2017,9(10):1756.[8]<中国药物经济学评价指南>课题组,刘国恩,胡善联,等.中国药物经济学评价指南(2011版)[J].中国药物经济学,2011(3):6-48,11-48.[9]Afsana A,Mohammed JA,Dianna JM,et al.Cost-of-illness of type 2 diabetes mellitus in low and lower-middle income countries:a systematic review[J].BMC Health Serv Res,2018,18(1):972.[10]万小敏,谭重庆,曾小慧,等.药物经济学评价概率敏感度分析中关联参数的参数分布[J].中国新药与临床杂志,2018,37(3):177-179.[11]黄菊青,李春容,陈金燕.头孢克肟治疗女性急性单纯性尿路感染38例临床分析[J].中国抗生素杂志,2006,31(12):765-767.[12]Erik HK, Adam DT,Nicolas SC,et al.Structure and Dynamics of FosA-Mediated Fosfomycin Resistance in Klebsiella pneumoniae and Escherichia coli[J].Antimicrob Agents Chemother,2017,61(11):1572-1617.[13]徐教睿.口服磷霉素氨基丁三醇治疗尿路感染[J].中国医院药学杂志,2014,34(3):244-246.[14]吴艺燕.左氧氟沙星不良反应78例分析及临床合理用药[J].吉林医学,2020,41(5):1152-1153.[15]Theresa AR,Manisha JM.Urinary tract infection in older adults[J].Aging Health,2013,9(5):686-693.[16]Wieslawa D,Victor DR,Michal F,et al.Device associated -health care associated infections monitoring, prevention and cost assessment at intensive care unit of University Hospital in Poland (2015-2017)[J].BMC Infect Dis,2020,20(1):761.[17]Antonio G.Recurrent urinary tract infections in women: risk factors, etiology, pathogenesis and prophylaxis[J].Future Microbiol,2017(12):239-246.[18]Enrique A,Maria TM,Giancarlo M,et al.Supramolecular Recognition of Escherichia coli Bacteria by Fluorescent Oligo(Phenyleneethynylene)s with Mannopyranoside Termini Groups[J].Sensors (Basel),2017,17(5):1025.[19]杨文中.左氧氟沙星注射液药物不良反应发生及其影响因素分析[J].山西医药杂志,2018,47(17):2023-2025.[20]David S,Marc H,Iris B,et al.Predictors of in-hospital mortality in elderly patients with acute venous thrombo-embolism: the SWIss Venous ThromboEmbolism Registry (SWIVTER)[J].Eur Heart J,2012,33(7):921-926.

相似文献/References:

[1]尹利娟,杨振华,杨乐园.2014~2016年嗜麦芽窄食单胞菌感染临床分布及耐药性分析[J].医学信息,2018,31(03):128.[doi:10.3969/j.issn.1006-1959.2018.03.044]
　YIN Li-juan,YANG Zhen-hua,YANG Le-yuan.Clinical Distribution and Drug Resistance Analysis of Stenotrophomonas Maltophilia Infection from 2014 to 2016[J].Medical Information,2018,31(02):128.[doi:10.3969/j.issn.1006-1959.2018.03.044]
[2]孙 赟,朱振国,余春兰,等.基于电子病历系统的抗菌药物分级管理系统开发及应用[J].医学信息,2018,31(07):18.[doi:10.3969/j.issn.1006-1959.2018.07.006]
　SUN Yun,ZHU Zhen-guo,YU Chun-lan,et al.Development and Application of Antibiotic Grading Management System Based on Electronic Medical Record System[J].Medical Information,2018,31(02):18.[doi:10.3969/j.issn.1006-1959.2018.07.006]
[3]严 威,靳 情.医院内泌尿道感染患者的病原菌耐药性分析[J].医学信息,2018,31(11):118.[doi:10.3969/j.issn.1006-1959.2018.11.037]
　YAN Wei,JIN Qing.Analysis of Pathogenic Bacteria Resistance of Patients with Urinary Tract Infection in Hospital[J].Medical Information,2018,31(02):118.[doi:10.3969/j.issn.1006-1959.2018.11.037]
[4]曹 蕾.医院信息化管理系统促进抗菌药物合理使用的价值分析[J].医学信息,2018,31(17):31.[doi:10.3969/j.issn.1006-1959.2018.17.010]
　CAO Lei.Value Analysis of Hospital Information Management System Promoting Rational Use of Antimicrobial Agents[J].Medical Information,2018,31(02):31.[doi:10.3969/j.issn.1006-1959.2018.17.010]
[5]王永艳,鱼兆虎.抗菌药物审批管理软件的设计与实现[J].医学信息,2019,32(12):21.[doi:10.3969/j.issn.1006-1959.2019.12.007]
　WANG Yong-yan,YU Zhao-hu.Design and Implementation of Antibacterial Drug Approval Management Software[J].Medical Information,2019,32(02):21.[doi:10.3969/j.issn.1006-1959.2019.12.007]
[6]王 蕊,陈金萍.2016~2017年脊柱手术预防用药及术后感染情况分析[J].医学信息,2018,31(24):112.[doi:10.3969/j.issn.1006-1959.2018.24.032]
　WANG Rui,CHEN Jin-ping.Analysis of Orophylactic Medication and Postoperative Infection in Spinal Surgery from 2016 to 2017[J].Medical Information,2018,31(02):112.[doi:10.3969/j.issn.1006-1959.2018.24.032]
[7]尹利娟,杨振华,杨乐园.2017年我院肠杆菌科细菌临床分布及耐药性分析[J].医学信息,2019,32(01):136.[doi:10.3969/j.issn.1006-1959.2019.01.042]
　YIN Li-juan,YANG Zhen-hua,YANG Le-yuan.Analysis of Clinical Distribution and Drug Resistance of Enterobacteriaceae in Our Hospital in 2017[J].Medical Information,2019,32(02):136.[doi:10.3969/j.issn.1006-1959.2019.01.042]
[8]王永宁,王瑞文,薛 郡,等.天津地区某基层医院铜绿假单胞菌的5年耐药变迁[J].医学信息,2019,32(09):124.[doi:10.3969/j.issn.1006-1959.2019.09.041]
　WANG Yong-ning,WANG Rui-wen,XUE Jun,et al.Five-year Resistance Change of Pseudomonas Aeruginosa in a Primary Hospital in Tianjin[J].Medical Information,2019,32(02):124.[doi:10.3969/j.issn.1006-1959.2019.09.041]
[9]彭洪兴.运用PDCA降低住院患者抗菌药物使用率及使用强度的临床实践[J].医学信息,2019,32(09):149.[doi:10.3969/j.issn.1006-1959.2019.09.049]
　PENG Hong-xing.Clinical Practice of Using PDCA to Reduce the Use Rate and Intensity of Antibiotics in Hospitalized Patients[J].Medical Information,2019,32(02):149.[doi:10.3969/j.issn.1006-1959.2019.09.049]
[10]樊凌燕,钱 鑫,熊世娟,等.2017年贵州省某综合型医院细菌耐药性监测及动态分析[J].医学信息,2019,32(10):136.[doi:10.3969/j.issn.1006-1959.2019.10.045]
　FAN Ling-yan,QIAN Xin,XIONG Shi-juan,et al.Monitoring and Dynamic Analysis of Bacterial Resistance in a General Hospital in Guizhou Province in 2017[J].Medical Information,2019,32(02):136.[doi:10.3969/j.issn.1006-1959.2019.10.045]

更新日期/Last Update: 1900-01-01